Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 for postherpetic neuralgia
CTR20212551Phase 3Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crisugabalin besilate in postherpetic neuralgia (PHN) (4 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in average daily pain score (ADPS) at week 12. Started Oct 2021; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on CTR20212551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212551.